Kisspeptin: The "Desire Hormone" Researchers Can't Stop Talking About
It has the most flirtatious name in endocrinology, and it may live up to it. Kisspeptin is a natural hormone that sits at the very top of your reproductive system, and in small human studies it appears to do something no current libido drug does: quiet the part of your brain that overthinks sex.
Evidence Grade: Small human studies. Not FDA-approved for any use. Promising early trials in women, with bigger studies the obvious next step.
What Is Kisspeptin?
Kisspeptin is a peptide your brain makes. Researchers call it a master regulator of reproduction because it sits at the top of the hormone chain that controls ovulation, estrogen and testosterone (Society for Endocrinology).
Because it also acts in brain regions linked to emotion and arousal, a team at Imperial College London started asking a bold question: could it help people whose desire has gone quiet?
What the Human Research Shows
Low desire in women. In a randomized, double-blind study published in JAMA Network Open in February 2023, 32 premenopausal women aged 19 to 48 with hypoactive sexual desire disorder (HSDD) each had two visits: one with a 75-minute intravenous kisspeptin infusion and one with a placebo (UPI; Society for Endocrinology). While watching erotic videos in a brain scanner:
• Kisspeptin dialed down activity in self-monitoring and self-judgment regions of the brain.
• It turned up activity in areas tied to sexual arousal.
• Women reported feeling significantly “sexier.”
• The women most distressed by their low libido showed the biggest response.
“Kisspeptin relieves the brake on true sexual arousal,” co-author Dr. Alexander Comninos told UPI. A companion study in 32 men with low desire found similar brain effects, plus measurable physical arousal.
Fertility. Kisspeptin is also being studied as a gentler egg-maturation trigger in IVF. In a study of 60 women at high risk of ovarian hyperstimulation syndrome (OHSS), a dangerous IVF complication, none developed moderate or severe OHSS after a kisspeptin trigger. The average live birth rate was 45%, and 62% at the best-performing dose (Society for Endocrinology, 2015). Researchers said larger trials are needed to compare it head-to-head with the standard trigger.
It’s also being explored for missing periods (hypothalamic amenorrhea) and other reproductive conditions, though those remain research areas, not treatments.
Why This Is Exciting
The two FDA-approved desire drugs for premenopausal women work differently. Vyleesi (bremelanotide, our PT-141 deep dive) can cause nausea, and Addyi can cause low blood pressure and dizziness (UPI). Kisspeptin appears to work on the brain’s own arousal wiring, using a hormone your body already makes. The Imperial team has said they want to develop an at-home, as-needed version and estimated it could be five to 10 years away.
Side Effects: What to Know
• In these short, supervised studies, kisspeptin was well tolerated. Lead researcher Prof. Waljit Dhillo said it “appears to be side-effect free” in that setting (UPI).
• That’s based on single, monitored doses, mostly by IV in a hospital. Repeated or long-term use hasn’t been studied.
• Because kisspeptin drives reproductive hormones, effects on cycles, fertility and hormone-sensitive conditions are real open questions for anyone using it outside a trial.
• Kisspeptin sold online as “research use only” isn’t regulated. Purity, contents and sterility can’t be confirmed, which brings its own risks: infection, contamination and allergic reactions.
When Should You Be Concerned?
Seek urgent care for trouble breathing, facial or throat swelling, hives, or chest
pain. Talk to a clinician promptly about:
• Redness, heat, pus or a growing lump at an injection site
• Unexpected bleeding or major changes to your cycle
• Severe headache, pelvic pain or bloating
• Any chance you could be pregnant
If low desire is bothering you, that’s worth raising with a clinician on its own. HSDD is a real, treatable diagnosis, and there are approved options.
What We Still Don’t Know
We know: in small, controlled human studies, kisspeptin changed how the brain responds to sexual cues, women felt sexier, and it showed promise as a safer IVF trigger.
The frontier: whether those brain changes translate into more desire in everyday life, whether repeated doses work and stay safe, and whether easier forms (an injection under the skin or a nasal spray) perform as well. The Imperial researchers also want to test it in broader groups of women. This is one of the most interesting desire stories in hormone science right now.
The Bottom Line
Kisspeptin isn’t a love potion, and it isn’t approved for anything yet. But the early human data are genuinely intriguing: a natural hormone that may lift the mental brake on desire. Keep it on your watch list.
Your turn: If a hormone could quiet the overthinking and let desire back in, would you try it once it’s approved?
This post is for educational purposes only and is not medical advice.
Sources
Read next: PT-141
Comments